Background--Thymic stromal lymphopoietin (TSLP) is a cytokine with multiple effects on the body. For one thing, TSLP induces Th2 immunoreaction and facilitates allergic reaction; for another, it promotes the differentiation of naturally occurring CD4 + CD25 + Foxp3 + regulatory T cells (nTregs) and maintains immune tolerance. However, the exact role of TSLP in atherosclerosis remains unknown.
A therosclerosis is an inflammatory condition of the arterial wall involving the cells of the innate and adaptive immune system. It is now widely recognized that chronic inflammation caused by T-cell-mediated pathogenic responses plays an important role in atherogenesis. 1 Recently, the pathogenic function of Th1 cells in atherosclerosis has been convincingly demonstrated in murine systems. 2, 3 Additional evidence supports that Th17 cells and interleukin (IL)-17, which are related to autoimmunity diseases, may play an important role in atherogenesis. 4 In contrast, other studies have demonstrated an atheroprotective effect for Th2 cells, CD4 + CD25 + Foxp3 + Tregs, and CD4 + latency-associated peptide (LAP) + Tregs. [5] [6] [7] Dendritic cells that are professional antigen-presenting cells present different capacities based on different subtypes: mature dendritic cells promote the differentiation of effector T cells, whereas the function of immature or semimature dendritic cells (tolerogenic DCs) is to maintain peripheral T-cell tolerance. 8 Tolerogenic dendritic cells (tDCs) excrete large amounts of IL-10 and transforming growth factor-b (TGF-b) and have an impaired ability to produce IL-12p70. 9 It has been demonstrated that conditioning dendritic cells with TGF-b 10 or IL-10 11 promotes tDCs that induce Th2 cell responses or the differentiation of CD4 + CD25 + Foxp3 + regulatory T cells (nTregs). Moreover, tDCs are able to prevent acute graft-versus-host disease 12 and autoimmune diabetes. 13 Recently, Hermansson et al found that the injection of tolerogenic antigen-loaded dendritic cells attenuates atherosclerosis. 14 Thus, tDCs may provide a new treatment to prevent atherosclerosis. As a member of the IL-7 cytokine family, thymic stromal lymphopoietin (TSLP) is principally expressed by epithelial cells mainly in the lung, skin, and gut. 15, 16 TSLP signals via a TSLP receptor, which consists of a heterodimer of the IL-7 receptor a chain and the TSLP receptor chain and is widely distributed on many immune cells, including DCs, T cells, B cells, and mast cells as well as in tissues from the heart. In the thymus, TSLP is selectively produced by epithelial cells of Hassall's corpuscles, and TSLP-activated dendritic cells (TSLP-DCs) induced differentiation of CD4 + Foxp3 À thymocytes into CD4 + Foxp3 + Tregs. 17 Recently, Taylor et al 16 demonstrated that TSLP could maintain mucosa tolerance through inhibiting Th1 and Th17 cells. In addition, Besin et al 18 found that TSLP and TSLP-conditioned DCs could protect NOD mice against diabetes by inducing nTreg and Th2-cell differentiation in the thymus and, subsequently, in peripheral organs (spleen and lymph nodes). These studies indicated that TSLP could affect the function of DCs and the differentiation of naive T cells directly or indirectly. Given these findings, we investigated whether murine TSLP and TSLP-DCs alleviate atherosclerosis via rectifying the imbalance between regulatory T cells and Th1 cells. We found that TSLP treatment induced Tregs (nTregs and CD4 + LAP + Tregs) and Th2 cells. In addition, the treatment prevented atherosclerosis through a TGF-b-dependent mechanism in apolipoprotein E-deficient (ApoE À/À ) mice. Our study is the first to find that TSLP inhibits atherosclerotic plaque formation by inducing a tolerogenic immune response in ApoE À/À mice.
Methods

Reagents and Antibodies
The cell culture medium for DCs and splenocytes was RPMI 1640 (Gibco) supplemented with 10% FCS (Gibco) and 100 U/mL streptomycin/penicillin. Human copper-oxidized low-density lipoprotein (oxLDL) was obtained from Yuanyuan Biotechnology of Zhongshan University (Guanzhou, China). In brief, LDL was collected from the plasma of a healthy volunteer, 19 and then isolated LDL was oxidized by 10 lmol/ L copper sulfate for 24 hours at 37°C. 20 GM-CSF (lot no.
050755-1), IL-4 (lot no. 1106CY49), and IL-2 (lot no. 0608108) were obtained from Peprotech (Rocky Hill, NJ). Recombinant mouse TSLP (lot no. ELR0511061), anti-TSLPbiotin antibody (cat no. BAF555), and anti-LAP-PE antibody (lot no. AACP0809111) were from R&D Systems. Purified anti-CD4 antibody (clone RM4-5) was from BD Systems (Franklin). Anti-CD11c-FITC antibody (clone N418), anti-C-D86-PE antibody (clone PO3. 
Animals
Male C57BL/6 mice and ApoE À/À mice from a C57BL/6 background (Jackson Laboratory) were bred and maintained in the Animal Center of Beijing University. The mice were kept in-house in a specific pathogen-free facility (Tongji Medical College) and were fed a normal chow diet or a Western-type diet containing 0.15% cholesterol and 21% fat. The mice were 6 weeks old at the start of the experiment. Diet and water were administered ad libitum. All experiments were carried out in compliance with the guidelines of the Care and Use of Laboratory Animals (Science and Technology Department of Hubei Province, China).
Generation of Bone Marrow-Derived DCs
Bone marrow-derived DCs were generated with GM-CSF and IL-4 as previously described. 21 In brief, bone marrow was isolated from ApoE À/À mice. Bone marrow cells were depleted of red blood cells and were cultured with RPMI 1640 for 6 days in tissue culture plates at 37°C and 5.0% CO 2 ; 1640 culture medium was supplemented with 10% FCS, 100 U/mL penicillin, 100 U/mL streptomycin, 10 ng/mL granulocyte-macrophage colony-stimulating factor, and 10 ng/mL IL-4. Purification of DCs from the differentiated bone marrow cells was performed with a CD11c magnetic cell-sorting kit (Miltenyi Biotec) according to the manufacturer's instructions. After purification, dendritic cells were left unstimulated (immature DCs [iDCs]) or exposed (48 hours) to 100 lg/mL oxLDL (oxLDL-DCs) or 20 ng/mL TSLP (TSLP-DCs) in RPMI 1640. After 48 hours, the supernatants were collected for ELISA analysis. 
T-Cell and
Animal Groupings
For analysis of TSLP expression, 6-week-old male C57BL/6 mice were given normal chow diet or a Western-type diet for 10 weeks, and ApoE À/À mice were given a Western-type diet.
Six-week-old male ApoE À/À mice were injected subcutaneously in the nuchal area with recombinant mouse TSLP (600 ngÁ250 lL À1 Ámouse À1 Áday À1 ) or PBS for 6 consecutive days. For the dendritic cell transfer experiments, 6-week-old male ApoE À/À mice received 1 intravenous injection of iDCs, TSLP-DCs, oxLDL-DCs (2910 6 cells/mouse), or PBS alone (the no-DC group). For the neutralization experiment, the mice were subcutaneously given 600 ng of TSLP daily for 6 days and then were injected with 100 lg of neutralizing anti-TGF-b antibody or control rat IgG once a week from the age of 7 to 16 weeks. Five days after treatment with TSLP or DCs, a Western-type diet was administered for 10 weeks. There were 6 to 9 mice in each group.
Real-Time Polymerase Chain Reaction
Total RNA from dendritic cells, splenocytes, the heart, or the abdominal aorta of each mouse was prepared using Trizol Plus (Takara). cDNA was transcribed from purified RNA using an RNA PCR Kit (Takara). Real-time polymerase chain reaction (PCR) was performed using One
Step SYBR Green Mix (Takara) and ABI Prism 7900 Sequence Detection System (Applied Biosystems) according to the manufacturers' instructions. Melting curves established the purity of the amplified band after 40 cycles of 30 seconds at 94°C, 30 seconds at 57°C, and 30 seconds at 72°C. Amplification reactions were performed in duplicate, and all mRNA expression was calculated using the comparative CT method formula 2
ÀΔΔct
. The data were presented and normalized to GAPDH. All primers used are shown in Table 1 .
Western Blot
Total protein of heart tissue and thoracic aorta was extracted with a Total Protein Extraction Kit (Pierce/Thermo Scientific). Protein concentration was determined by a BCA Protein Assay Kit (Pierce). Samples containing 50 g of protein were separated on a 10% SDS-PAGE and electrotransferred onto nitrocellulose membranes. Membranes were sequentially blocked in TBST containing 5% skim milk and then incubated with anti-TSLP-biotin antibody (1:1000; R&D Systems) and anti-b-actin (1:1000; Abcam) at 4°C overnight. After washing, the membranes were then further incubated with HRPconjugated secondary antibody (1:5000, 37°C, 2 hours). The target bands were finally washed and developed with super ECL reagent (Thermo Scientific) and semiquantitatively analyzed using densitometric methods. complete culture medium. The cell suspension in 1 mL of medium was transferred to each well of 24-well plates. Cultures were stimulated with phorbol myristate acetate (20 ng/mL) plus ionomycin (1 lg/mL) from Alexis Biochemicals for 4 hours in the presence of 2 lmol/mL monensin (Alexis Biochemicals). The incubator was set at 37°C under a 5% CO 2 environment. After 4 hours of culture, the monocytes were collected for staining according to the instructions. Fixation and permeabilization were necessary before staining with IFN-c, IL-4, or IL-17 antibody. Isotype controls were given to enable correct compensation and confirm antibody specificity. For analysis of the characterization for cultured DCs, the purified CD11c cells were stained with CD86-PE or PD-L1-PE for 30 minutes. Flow cytometric acquisition was performed using a FACSCalibur (BD Immunocytometry Systems), and all analyses were performed using Flowjo software (Treestar Inc).
Weight and Lipids
The weight of each mouse was recorded 2, 4, 6, 8, 10 weeks following the start of the Western-type diet. The plasma was isolated from the blood of mice by centrifugation at 1200g for 10 minutes after clotting at room temperature. Total cholesterol, high-density lipoprotein cholesterol, and triglyceride plasma levels were measured by enzymatic assay and determined with an autoanalyzer (Hitachi 917).
Atherosclerotic Lesion and Heart Tissue Analysis
Atherosclerosis lesions were quantified in the aortic sinus and descending thoracic aorta, as previously described. 23 In brief, the hearts including the aortic roots, which were parallel to the atria, were prepared, and sections were fixed in 4% formaldehyde, processed, and embedded in optimum cutting temperature (OCT) compound. Five-to seven-micrometer sections of the aortic sinus were cut at 35-lm intervals starting from the 3-valve cusps. In addition, the descending thoracic aorta were dissected and fixed, opened longitudinally, and pinned onto black wax plates. All the above specimens were stained with Oil Red O and hematoxylin. 
Statistical Analysis
Results are expressed as the meanAESD unless indicated otherwise. Comparisons between 2 groups were performed by the Student t test when data were normally distributed and group variances were equal. The Mann-Whitney rank sum test was used when data were not normally distributed or if group variances were unequal. One-way ANOVA was used for multiple comparisons between ≥3 groups followed by the Holm-Sidak test when data were normally distributed and group variances were equal. The Kruskal-Wallis test followed by the Dunn test was used when group data were not normally distributed or if group variances were unequal. The software used for statistical analysis was GraphPad Prism 6.0. The significance level was set at P<0.05.
Results
TSLP Is Almost Absent in Cardiovascular Tissue of ApoE À/À Mice
TSLP is expressed predominantly by epithelial cells in the thymus, lung, skin, and intestine as well as stromal cells. 24 However, the expression of TSLP in atherosclerotic tissue has not been previously investigated.
We examined the expression of TSLP in murine by PCR, Western blot, and immunohistochemistry. Immunostaining and quantitative PCR demonstrated significantly lower expression of TSLP in hearts from ApoE À/À mice fed a Western-type diet versus C57BL/6 control mice or C57BL/6 mice with a Western-type diet ( Figure 1A and 1B) . In addition, the results of the Western blot were similar to the immunostaining ( Figure 1C ). Meanwhile, expression of TSLP was detected in the aorta. Surprisingly, very few TSLP + cells were detected in the aortic roots of ApoE À/À mice, whereas abundant expression was found in the hearts of C57BL/6 mice irrespective of Western-type diet ( Figure 1D ), and TSLP mRNA was also inhibited in the aortas of ApoE À/À mice ( Figure 1E ).
Furthermore, the results of the Western blot were similar to the immunostaining ( Figure 1F ).
Characterization of Cultured DCs
As oxLDL promotes dendritic cells to maturate and differentiate strongly 25 Figure 3B ) and almost 7-fold more CD4 + LAP + Tregs (3.67AE0.56% versus 0.52AE0.20%, P<0.0001; Figure 3C ). In addition, CD4 + T cells cocultured with TSLP-DCs produced a 4-fold greater amount of IL-4 and low amounts of IFN-c ( Figure 3D ). In addition, only moderate proliferation of CD4 + T cells was induced by
anti-CD3 and IL-2, whereas a combination of anti-CD3 and IL-2 with iDCs, TSLP-DCs, or oxLDL-DCs induced 3.3-, 3.5-, and 3.7-fold increases in CD4 + T-cell proliferation, respectively ( Figure 3E Figure 4A and 4B). Simultaneously, the atherosclerotic lesions of TSLP-treated mice showed a marked 25% reduction in the accumulation macrophages (28.25AE9.72% versus 53.13AE12.29%, P=0.0005; Figure 4A and 4C) and also a 3-fold increase in Foxp3 + Treg cell infiltration ( Figure 4A and 4D) . Furthermore, we performed a-smooth muscle actin, Masson, CD4, and CD11c staining of the plaques and found no statistically significant difference in staining between TSLP-treated mice and PBS-treated mice ( Figures 4A, 4E , 4F, and 5). In addition, we also observed a lower plaque burden in thoracic aorta when giving TSLP treatment ( Figure 5 ). TSLP also affected body weight growth (5.3AE0.8 versus 7.3AE1.3 g, P=0.0053; Table 2 ), but did not affect total plasma cholesterol, high-density lipoprotein cholesterol, and triglycerides (Tables 3, 4 , and 5). Figure 6A and 6C). There were no significant a-smooth muscle actin, collagen, and CD11c changes in each group ( Figures 6A, 6E , 6F, and 7). Similar to TSLP treatment, administration of TSLP-DCs also led to a slight but not significant decrease in CD4 + T cells (Figure 7) . In thoracic aorta, TSLP-DCs also led to a lower plaque burden compared with controls ( Figure 7) . Interestingly, TSLP-DC treatments slightly decreased body weight growth (5.2AE1.1 versus 7.4AE0.8 g; Table 2 ) and did not affect total plasma cholesterol, high-density lipoprotein cholesterol, and triglycerides (Tables 3, 4 , and 5) in ApoE Figure 8C) . Surprisingly, similar results were discovered in the spleens of mice administered TSLP-DC treatment ( Figure 9 ). In contrast, oxLDL-DC injection promoted proinflammatory Th1 cells (29.0AE2.6% versus 23.8AE2.4%, P=0.0058; Figure 9B ) and did not affect the Figure 9C ).
TSLP-DCs Prevent Atherosclerosis in ApoE
The Atheroprotective Effect of TSLP Is Associated With Downregulation of Systemic Inflammation
We tested changes in inflammatory cytokines in the spleen, plasma, and descending aorta. In plasma, the levels of TGF-b1 and IL-4 were increased and detectable in mice that received TSLP ( Figure 10A and 10B) or TSLP-DCs ( Figure 10C and 10D) , whereas levels of IFN-c and IL-12 were very low and nearly undetectable. In contrast, oxLDL-DC injection increased IFN-c and IL-12 levels, and they were detectable ( Figure 10C ). We found that mRNA expression of TGF-b1 was slightly upregulated in the spleens and descending aortas of mice that received oxLDL-DCs compared with controls. mRNA levels were significantly upregulated in mice that received TSLP injection ( Figure 10E and 10F) and TSLP-DC treatment ( Figure 10G and 10H) . Surprisingly, the expression of another anti-inflammatory factor, IL-10, was similar to that of TGF-b1. Furthermore, oxLDL-DC administration increased the expression of IFN-c in the spleen and aorta, but TSLP and TSLP-DC treatments inhibited this effect ( Figure 10E through 10H) . The expression of Foxp3 in aorta was very low in mice from other groups except for the mice administered TSLP ( Figure 10E ). The injection of oxLDL-DCs also promoted IL-12 expression in the spleen and aorta, but TSLP-DCs did not ( Figure 10G and 10H).
OxLDL-Specific Antibodies Are Induced in the Plasma of ApoE À/À Mice by TSLP Treatment
Atherosclerosis is related to antibody formation of oxidatively modified LDL, and the levels of this antibody can predict the progression of atherosclerosis in humans. 26 All the above assayed effects involved TSLP modulating cellular immunity, but we also investigated whether there was a humoral immunity response to TSLP treatment by quantifying plasma antibody titers. Th1 cells induced IgG 2a production, whereas Th2 cells facilitated IgG 1 and IgE synthesis. Here we assessed the levels of oxLDL-specific antibodies. Our results indicated that more IgM and IgG 1 but less IgG 2a were produced in TSLP-treated mice compared with the controls 2 weeks after TSLP administration ( Figure 10I ). 
Neutralization of TGF-b In Vivo Abrogates the Effect of TSLP on Atherosclerosis
Our PCR and ELISA data for cytokine production in vivo and in vitro indicated that TGF-b is increased markedly by TSLP treatment. In addition, previous studies indicated that TGF-b plays a crucial role in the suppressive function of nTregs 27 and CD4 + LAP + Tregs. 28 To determine whether TGF-b is directly involved in inhibiting plaque formation after TSLP treatment, we performed a TGF-b neutralization study. TSLP-treated mice that received anti-TGF-b neutralizing antibody presented significantly increased atherosclerotic lesion formation and macrophages and CD4 + T-cell accumulations in the plaques, compared with TSLP-treated mice receiving isotype-matched antibodies ( Figure 11 ). Tregs indirectly via tolerogenic DCs, which produce large amounts of TGF-b. 18 These findings suggest that TSLP receptors exist not only on DCs but also on CD4 + T cells. In combination with our results, we will discuss the functional relevance of TSLP, DCs, nTregs/CD4 + LAP + Tregs, and TGF-b in atherosclerotic mice. In addition to the effects on cellular immunity, we found that humoral immunity is also affected by TSLP. First, we investigated the expression of TSLP in atherosclerotic mice with ApoE knockout and hypercholesterolemic features. We found that TSLP was nearly absent in ApoE À/À mice but was expressed normally in C57BL/6 mice. This led to doubt about whether the disorder of lipid metabolism contributes to the inhibition of TSLP in atherosclerotic mice compared with C57BL/6 mice. Similarly, Turcot et al 31 discovered lower TSLP expression in visceral adipose tissue from obese men compared with those without metabolic syndrome. Many studies have also implicated type 2 cytokines such as IL-33 as having beneficial effects on obesity and metabolism through inducing the accumulation of Th2 cells and alternatively activated macrophages (M2) in adipose tissue. 32 Although these findings are associated with ours, including a slight but not significant triglyceride decrease and obvious weight restriction by TSLP administration, further studies will be needed to validate the function of TSLP in the inflammation in obesity.
In humans and mice, stimuli such as oxLDL 25 limiting APC-dependent T-cell activation. 36 All these results are signs of functional tDCs. This means that the expansion and differentiation are both indispensable in the induction of nTregs. Previously, TSLP, which is involved in allergic disease through Th2 modulation, 34, 35 was considered an "inflammatory" factor. However, additional studies have indicated that TSLP plays a key role in immune tolerance in several murine sites, including the intestine, thymus, and colon. 16, 17, 30 27 Given previous findings, 17, 18, 30 it is likely that the increase in nTregs originated from not only the central immune organ (thymus) but also from regions in the periphery (intestinal mucosa, lymph nodes, spleen). Recently, TGF-b, which is produced by many types of cells in atherosclerotic plaques, has been drawing much attention as a potent protective cytokine in atherosclerosis. 38 In particular, the deletion of TGF-b signaling in T cells accelerated plaque formation and inflammatory cell infiltration. Furthermore, other studies revealed that TGF-b also suppressed foam cell formation and increased collagen biosynthesis. 6, 39 TGF-b in association with an increase of Foxp3+ Tregs in plaques found in our study could establish a noninflammatory environment in atherosclerotic lesions. This led to decreased CD4 + T-cell infiltration and macrophage-derived foam cell formation and a slight increase in collagen content although not statistically significant. Although TGF-b does not promote smooth muscle proliferation, it encourages expression of type I TGF-b receptors on smooth muscle cells but not type II receptors, which induces collagen production and a stable plaque phenotype. 38 This was proven when atheroprotection was abrogated and the percentage of macrophages and CD4 + T-cell number in the plaques increased after neutralization of TGF-b. Unlike in previous studies, 7 our data did not indicate inhibition of Th17 cells in the TGF-b environment in atherosclerotic mice. Furthermore, the increased percentage of Th2 cells in the spleen and increased expression of non-inflammatory factors IL-4 and IL-10 by TSLP or TSLP-DC treatment implied a differentiation of Th2 cells, which would benefit the progression of atherosclerosis, as Th1 and Th2 cells reciprocally inhibit each other. 40 In the present study, Th2 cells or a switch from Th1 to Th2 may have protected against atherosclerosis by limiting the Th1 cell response. 41, 42 Given the inhibitory effect of Tregs on Th1, it was not difficult to understand the decreased Th1 cells observed in the spleen and the decreased IFN-c in the aorta. In the TSLP treatment group, high levels of plasma oxLDL-specific antibodies, especially Th2-type IgG 1 and IgM, were detected. Recently, Miller et al 43 found that IL-33 reduced atherosclerosis by inducing IL-5-dependent IgG 1 . In rabbit and murine models, it has been shown that immunization with oxLDL induces antibody formation (both IgG and IgM) and protects against the development of atherosclerosis. 44 Here, TSLP protected against the development of atherosclerosis partly through the differentiation of Th2 cells and, subsequently, the production of Th2-type antibodies. In summary, our study is the first to highlight that TSLP atheroprotection in atherosclerosis is mediated through tolerogenic dendritic cells that increase protective CD4 + LAP + Tregs and nTregs and promote inflammatory Th1 cell change into noninflammatory Th2 cells. This modulation facilitates a Th2 humoral immune response.
